CN111714515A - Blood purification molecule concentrate and preparation method and application thereof - Google Patents
Blood purification molecule concentrate and preparation method and application thereof Download PDFInfo
- Publication number
- CN111714515A CN111714515A CN202010446821.3A CN202010446821A CN111714515A CN 111714515 A CN111714515 A CN 111714515A CN 202010446821 A CN202010446821 A CN 202010446821A CN 111714515 A CN111714515 A CN 111714515A
- Authority
- CN
- China
- Prior art keywords
- citrate
- acid
- mmol
- blood purification
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A blood purification molecule concentrate, a preparation method and application thereof, belonging to the technical field of medical instruments. The invention relates to a blood purification molecule concentrate, which is a molecular substance-free acetic acid-free concentrate with a brand-new concept, is used for overcoming the defects of the prior art, and solves the defect that no molecular substance exists in the conventional dialysis concentrate. The invention has the technical characteristics that: the concentrate is a solid or liquid preparation, and contains pH regulator and molecular substances selected from one or two or more of L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, and calcium citrate or sodium citrate, magnesium citrate, and potassium citrate.
Description
Technical Field
The invention relates to a preparation, a preparation method and application thereof, in particular to a blood purification molecular concentrate, a preparation method and application thereof, and belongs to the technical field of medical instruments.
Background
Blood purification is to draw the patient's blood out of the body and pass through a purification device to remove pathogenic substances or waste in the blood and purify the blood to achieve the purpose of treating diseases. The blood purification includes treatment technologies such as hemodialysis, hemofiltration, hemodiafiltration and peritoneal dialysis, at present, the application of the blood purification technology is not only used for treating acute and chronic renal failure and uremia, but also becomes an important life science relating to multiple disciplines, and the blood purification technology can be used for treating various cross-discipline diseases such as nephropathy, hematopathy, hyperlipidemia, drug poisoning, continuous renal replacement therapy and the like.
At present, blood purification technology is widely applied, but molecular substances and acid-base regulators in bicarbonate blood purification molecular concentrates are not taken into consideration in dialysis, the molecular substances and the acid-base regulators are important components of solution balance and play very important roles in regulating osmotic pressure, preventing blood coagulation, maintaining pH value, regulating pH value and preventing metastatic calcification and calcium crystallization, a certain amount of acetic acid or glacial acetic acid is generally added in dialysis at present, acetate ions generated in the dialysis solution by the acetic acid or the glacial acetic acid are related to a plurality of complications of patients in and after dialysis, and as the acetate can stimulate the organism to release a plurality of active cytokines, such as PNF/PGE2, IL-1 and the like, the active factors play an important role in the pathology aspect of a plurality of dialysis complications, the acetic acid also influences the phosphorus metabolism of the dialysis patients, is one of the causes of chronic hyperphosphatemia. Meanwhile, acetic acid is metabolized in the liver, the burden of the liver is increased, the liver is stimulated, other clinical pathological manifestations are brought, molecular substances play an important role in the prevention of dialysis complications, dialysis hyperthyroidism can be prevented, and occurrence of metastatic calcification can be prevented, so that the problem that the dialysis needs to be solved urgently is solved by replacing acetic acid with certain acid, and the occurrence of acetic acid-free blood purification molecular concentrates is inevitable.
Disclosure of Invention
The invention aims to solve the technical problem of overcoming the defects of the prior art and providing a novel concept of hemodialysis acetic acid-free molecular concentrate, the blood purification molecular concentrate overcomes the defect that no molecular substance exists in the conventional dialysis concentrate, and the acid-base regulator used in the invention is a physiological organic acid or a physiologically necessary acid, exists in most fruit foods in the nature and has wide application in food addition and medicine.
The invention further provides a preparation method and application of the blood purification molecule concentrate.
The technical problem of the invention is realized by the following technical scheme.
The blood purification molecule concentrate is a solid preparation or a liquid preparation, and is characterized in that the blood purification molecule concentrate contains an acid-base regulator and a substance existing in a molecular form; the acid-base regulator is one or two or a mixture of L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid and calcium citrate or sodium citrate, magnesium citrate and potassium citrate.
The blood purification molecule concentrate is used for hemodialysis, hemofiltration, hemodiafiltration or peritoneal dialysis.
The blood purification molecule concentrate, the liquid state preparation and the solid state preparation have the following clinical application weights: 55-92% of sodium chloride, 0-3% of potassium chloride, 0.1-2% of magnesium chloride, 0.1-5% of calcium chloride, 0.1-15% of L-malic acid, 0.1-10% of DL-malic acid, 0.1-15% of maleic acid, 0.1-15% of fumaric acid, 0.1-15% of succinic acid, 0.1-10% of calcium citrate, 0.1-20% of sodium citrate, 0.1-20% of potassium citrate, 0.1-20% of magnesium citrate and 1-25% of glucose.
The blood purification molecule concentrate, the liquid state preparation and the solid state preparation have the clinically applied concentrations as follows: 100.0-145.0 mmol/L, K + 0.0-4.5 mmol/L, Ca2+ 0.5-2.5 mmol/L, Mg2+ 0.20-1.5 mmol/L, Cl-90.0-120.0 mmol/L, L-0.1-10.0 mmol/L, DL-0.1-10.0 mmol/L malic acid, 0.1-10.0 mmol/L maleic acid, 0.1-10.0 mmol/L fumaric acid, 0.1-10.0 mmol/L succinic acid, 0.1-10.0 mmol/L calcium citrate, 0.1-10.0 mmol/L sodium citrate, 0.1-10.0 mmol/L potassium citrate, 0.1-10.0 mmol/L magnesium citrate, 0.1-10.0 mmol/L, HCO 3-25.0-40.0 mmol/L glucose, 0-15.0 mmol/L glucose.
The method for preparing the blood purification molecule concentrate comprises the following steps:
(1) the preparation method of the solid preparation comprises the following steps: mainly comprises sodium chloride, potassium chloride, calcium chloride, magnesium chloride, L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, calcium citrate, sodium citrate, magnesium citrate, potassium citrate, sodium bicarbonate and glucose, is screened, mixed and sealed in a packaging container, and is dissolved and diluted by purified water or dialysis water when in use to prepare the concentration;
(2) the preparation method of the liquid preparation comprises the following steps: mainly comprises sodium chloride, potassium chloride, calcium chloride, magnesium chloride, L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, calcium citrate, sodium citrate, magnesium citrate, potassium citrate, sodium bicarbonate, glucose, purified water or dialysis water, is filled into a packaging container after being dissolved and filtered, and is diluted by purified water or dialysis water when in use to prepare the concentration.
Application of blood purification molecular concentrate in preparation of blood purification therapeutic apparatus
THE ADVANTAGES OF THE PRESENT INVENTION
1. The invention uses L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, calcium citrate, sodium citrate, magnesium citrate, potassium citrate, sodium bicarbonate, acid-base regulator and molecular substance as bicarbonate blood purification molecular concentrate, can well regulate the pH value, reach stable pH value, maintain osmotic pressure and solution balance, interact, prevent dialysis hyperthyroidism and metastatic calcification, effectively prevent calcium, magnesium ions and carbonate ions from combining to produce precipitation, form stable dialysis solution. Preventing blood coagulation and achieving safe treatment effect
2. The invention relates to an acetic acid-free blood purification molecule concentrate, which completely overcomes the complications caused by acetic acid radicals and the pathological manifestations of molecular-free substances in the treatment process compared with the traditional acetic acid radical-containing and molecular-free hemodialysis liquid.
All obvious changes and modifications which are obvious to the technical scheme of the invention are covered by the protection scope of the invention.
Claims (6)
1. A blood purification molecule concentrate, which is a solid state preparation or a liquid state preparation, and is characterized in that the blood purification molecule concentrate contains an acid-base regulator and a substance existing in a molecular form; the acid-base regulator is one or the mixture of two or more of L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, calcium citrate, sodium citrate, magnesium citrate and potassium citrate.
2. The blood purification molecule concentrate of claim 1, wherein the blood purification molecule concentrate is a preparation for hemodialysis, hemofiltration, hemodiafiltration, or peritoneal dialysis.
3. A blood purification molecule concentrate according to claims 1-2, wherein the liquid and solid formulations are in clinical use in the weight ratios: 55-92% of sodium chloride, 0-3% of potassium chloride, 0.1-2% of magnesium chloride, 0.1-5% of calcium chloride, 0.1-15% of L-malic acid, 0.1-15% of DL-malic acid, 0.1-15% of maleic acid, 0.1-15% of fumaric acid, 0.1-15% of succinic acid, 0.1-10% of calcium citrate, 0.1-20% of sodium citrate, 0.1-20% of potassium citrate, 0.1-20% of magnesium citrate and 1-25% of glucose.
4. A blood purification molecule concentrate according to claims 1-2, wherein the liquid and solid state formulations have clinically applied solute concentrations of: 100.0-145.0 mmol/L, K + 0.0-4.5 mmol/L, Ca2+ 0.5-2.5 mmol/L, Mg2+ 0.20-1.5 mmol/L, Cl-90.0-120.0 mmol/L, L-0.1-10.0 mmol/L, DL-0.1-10.0 mmol/L malic acid, 0.1-10.0 mmol/L maleic acid, 0.1-10.0 mmol/L fumaric acid, 0.1-10.0 mmol/L succinic acid, 0.1-10.0 mmol/L calcium citrate, 0.1-10.0 mmol/L sodium citrate, 0.1-10.0 mmol/L potassium citrate, 0.1-10.0 mmol/L magnesium citrate, 0.1-10.0 mmol/L, HCO 3-25.0-40.0 mmol/L citrate, and 0-15.0 mmol/L glucose.
5. A method of preparing a blood purification molecule concentrate according to any one of claims 1 to 4, comprising the steps of:
(1) the preparation method of the solid preparation comprises the following steps: mainly comprises sodium chloride, potassium chloride, calcium chloride, magnesium chloride, L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, calcium citrate, sodium citrate, magnesium citrate, potassium citrate, sodium bicarbonate and glucose, is screened, mixed and sealed in a packaging container, and is dissolved and diluted by purified water or dialysis water when in use to prepare the concentration;
(2) the preparation method of the liquid preparation comprises the following steps: mainly comprises sodium chloride, potassium chloride, calcium chloride, magnesium chloride, L-malic acid, DL-malic acid, maleic acid, fumaric acid, succinic acid, calcium citrate, sodium citrate, magnesium citrate, potassium citrate, sodium bicarbonate, glucose, purified water or dialysis water, is filled into a packaging container after being dissolved and filtered, and is diluted by purified water or dialysis water when in use to prepare the concentration.
6. Use of the blood purification molecule concentrate of any one of claims 1 to 5 for the preparation of a blood purification therapeutic device.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010446821.3A CN111714515A (en) | 2020-05-22 | 2020-05-22 | Blood purification molecule concentrate and preparation method and application thereof |
PCT/CN2021/095226 WO2021233432A1 (en) | 2020-05-22 | 2021-05-21 | Blood-purification molecular concentrate, preparation method therefor, and application thereof |
CN202180032036.6A CN115811988A (en) | 2020-05-22 | 2021-05-21 | Blood purification molecule concentrate and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010446821.3A CN111714515A (en) | 2020-05-22 | 2020-05-22 | Blood purification molecule concentrate and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111714515A true CN111714515A (en) | 2020-09-29 |
Family
ID=72564958
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010446821.3A Withdrawn CN111714515A (en) | 2020-05-22 | 2020-05-22 | Blood purification molecule concentrate and preparation method and application thereof |
CN202180032036.6A Pending CN115811988A (en) | 2020-05-22 | 2021-05-21 | Blood purification molecule concentrate and preparation method and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180032036.6A Pending CN115811988A (en) | 2020-05-22 | 2021-05-21 | Blood purification molecule concentrate and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN111714515A (en) |
WO (1) | WO2021233432A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021233432A1 (en) * | 2020-05-22 | 2021-11-25 | 夏永彪 | Blood-purification molecular concentrate, preparation method therefor, and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109106724A (en) * | 2017-06-23 | 2019-01-01 | 刘成其 | A kind of malic acid bicarbonate external hemodialysis agent |
CN109498646A (en) * | 2018-11-16 | 2019-03-22 | 秦皇岛迈淩医疗设备有限公司 | A kind of haemodialysis solid pharmaceutical preparation and preparation method thereof |
CN111714515A (en) * | 2020-05-22 | 2020-09-29 | 夏永彪 | Blood purification molecule concentrate and preparation method and application thereof |
-
2020
- 2020-05-22 CN CN202010446821.3A patent/CN111714515A/en not_active Withdrawn
-
2021
- 2021-05-21 WO PCT/CN2021/095226 patent/WO2021233432A1/en active Application Filing
- 2021-05-21 CN CN202180032036.6A patent/CN115811988A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021233432A1 (en) * | 2020-05-22 | 2021-11-25 | 夏永彪 | Blood-purification molecular concentrate, preparation method therefor, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2021233432A1 (en) | 2021-11-25 |
CN115811988A (en) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI326597B (en) | Bicarbonate-based solutions for dialysis therapies | |
Frank et al. | Further experiences with peritoneal irrigation for acute renal failure: including a description of modifications in method | |
Fassler et al. | Magnesium toxicity as a cause of hypotension and hypoventilation: occurrence in patients with normal renal function | |
AU664492B2 (en) | Method and composition for treating inflammatory bowel disorders | |
US6986905B1 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
ES2547607T3 (en) | Process for metabolic control and high purification of solutes and solutions for use in it | |
JP2013516463A (en) | Nutritional composition and method of use thereof | |
CN111714515A (en) | Blood purification molecule concentrate and preparation method and application thereof | |
WO2010112547A1 (en) | Dialysis precursor composition | |
CN116056715A (en) | Blood purification concentrate | |
CN101756949A (en) | Composition of ambroxol hydrochloride and cysteine and preparation method thereof | |
Lee et al. | Severe glyphosate-surfactant intoxication: successful treatment with continuous renal replacement therapy | |
CN103638526B (en) | A kind of blood purification preparation and preparation method thereof and application | |
RU2536994C1 (en) | Concentrated acidic component, kit for producing it, concentrated solution of acidic component for producing hemodialysis solution and method for producing it | |
EP0431465B1 (en) | Dialysation- and rinsing-solution for intraperitoneal administration | |
EP2965747A1 (en) | Dialysate acid precursor composition enriched with phosphorous | |
Schreiner et al. | The patient with chronic renal failure and surgery | |
CN111821532A (en) | Method for accurately adjusting sodium in replacement liquid formula | |
Davenport | Replacement and dialysate fluids for patients with acute renal failure treated by continuous veno-venous haemofiltration and/or haemodiafiltration | |
CN109106724A (en) | A kind of malic acid bicarbonate external hemodialysis agent | |
EP2609915B1 (en) | Dialysis and substitution fluid | |
Leunissen et al. | Chronic haemodialysis with bicarbonate dialysate: technical and clinical aspects | |
SCHLOERB | Peritoneal dialysis and newer methods of intestinal perfusion in renal failure | |
JP6890353B2 (en) | Composition for improving renal function of renal diseases containing molecular hydrogen | |
CN107854486A (en) | The medical composition and its use of the various trace elements of injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200929 |
|
WW01 | Invention patent application withdrawn after publication |